MedPage Today AMSTERDAM -- The novel intravenous direct factor Xa inhibitor otamixaban failed to make a difference in preventing ischemic events among patients with non-ST-segment elevation myocardial infarction when compared with heparin and eptifibatide ...
MedPage Today Patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS) randomized to otamixaban had similar rates of the composite primary efficacy outcome of death or new myocardial infarction as patients treated with unfractionated heparin plus ...
MedPage Today Moreover, unlike the VTE studies of apixaban and rivaroxaban, all patients in the Hokusai trial received heparin for 5 days. After that heparin run-in, patients were randomized to edoxaban or to warfarin. The median duration of heparin after ...
TCTMD AMSTERDAM, The Netherlands—In patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS) slated for invasive treatment, otamixaban does not offer superior efficacy over the combination of unfractionated heparin (UFH) and ...
PharmaTimes Along with enthusiasm for oral anticoagulants, there is also growing hope that injectable heparin might be safely eliminated, thus switching two inconvenie...
Medical Xpress Use of the novel anticoagulant otamixaban did not reduce ischemic events compared with unfractionated heparin plus eptifibatide but increased bleeding a...
Healio AMSTERDAM — Once-daily edoxaban administered after initial treatment with low–molecular-weight heparin was noninferior to standard therapy and associated with less bleeding in patients with venous thromboembolism, including those with severe ...
